Listar por tema "cytochrome P450 2D6"

Ordenar por:Orden:Resultados:

  • Cytochrome P450 2C19 poor metabolizer phenotype in treatment resistant depression: Treatment and diagnostic implications 
    Veldic, Marin; Ahmed, Ahmed T.; Blacker, Caren J.; Geske, Jennifer R.; Biernacka, Joanna M.; Borreggine, Kristin L.; Moore, Katherine M.; Prieto, Miguel L.; Vande Voort, Jennifer L.; Croarkin, Paul E.; Hoberg, Astrid A.; Kung, Simon; Alarcón, Renato D.; Keeth, Nicola; Singh, Balwinder; Bobo, William V.; Frye, Mark A. (Frontiers Media, 2019)
    Background: Pharmacogenomic testing, specifically for pharmacokinetic (PK) and pharmacodynamic (PD) genetic variation, may contribute to a better understanding of baseline genetic differences in patients seeking treatment ...
  • Single-dose tafenoquine to prevent relapse of plasmodium vivax malaria 
    Lacerda, M.V.G.; Llanos Cuentas, Elmer Alejandro; Krudsood, S.; Lon, C.; Saunders, D.L.; Mohammed, R.; Yilma, D.; Pereira, D.B.; Espino, F.E.J.; Mia, R.Z.; Chuquiyauri, R.; Val, F.; Casapía, M.; Monteiro, W.M.; Brito, M.A.M.; Costa, M.R.F.; Buathong, N.; Noedl, H.; Diro, E.; Getie, S.; Wubie, K.M.; Abdissa, A.; Zeynudin, A.; Abebe, C.; Tada, M.S.; Brand, F.; Beck, H.-P.; Angus, B.; Duparc, S.; Kleim, J.-P.; Kellam, L.M.; Rousell, V.M.; Jones, S.W.; Hardaker, E.; Mohamed, K.; Clover, D.D.; Fletcher, K.; Breton, J.J.; Ugwuegbulam, C.O.; Green, J.A.; Koh, G.C.K.W. (Massachusetts Medical Society, 2019)
    BACKGROUND: Treatment of Plasmodium vivax malaria requires the clearing of asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared from the liver (a treatment termed "radical cure"). Tafenoquine ...

Buscar en el Repositorio

Listar

Panel de Control